Skip to contentR
Relay Therapeutics, Inc.
R
RLAYRelay Therapeutics, Inc. Q1 2026 · 10-Q
Revenue$3.00M$3.00M−60.9% vs Q1 2025 Net Income-$73.29M-$73.29MN/M vs Q1 2025 EPS Diluted-$0.41-$0.41N/M vs Q1 2025 Operating Income-$78,590,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR
Margins · derivedOperating margin-2619.7%−1514.5 pt vs Q1 2025
Net margin-2443.0%−1439.5 pt vs Q1 2025
ended Mar 31, 2026 · filed May 5, 2026 · 35 d after period end